Update: CADTH introduced the time-limited reimbursement recommendation category on September 28, 2023.
The Canadian Agency for Drugs and Technologies in Health (CADTH) has released a consultation document for a Proposed Process for Time-limited Reimbursement Recommendations. The time-limited reimbursement recommendations would be contingent on a future reassessment with further evidence about the comparative clinical benefit and cost-effectiveness of the drug or drug regimen under review.
According to CADTH, the initiative for time-limited reimbursement recommendation will help ensure timely access to promising new therapies and would better align with conditional regulatory approval, including Health Canada’s initiatives on agile licensing of drugs.
Feedback should be provided using the feedback template by 5:00 pm ET on May 1, 2023.
Innovative Medicines Canada (IMC) released a report, Innovative Access Arrangements and Managed Entry—What Canada Can Learn From Europe, which outlines various arrangements made for reimbursement of drugs in Italy, England and Spain, and what lessons Canada could take from such arrangements. CADTH’s proposed time-limited reimbursement recommendation is an example of one of the arrangements discussed in the IMC report: coverage with evidence development, where the price and reimbursement terms for a drug are subject to review based on post-marketing trials or real-life data. As previously reported, IMC published an Innovative Agreements Framework describing various types of innovative agreements for drug reimbursement.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Minister of Health proposes legislation for first phase of national universal pharmacare
On February 29, 2024, the Minister of Health announced the introduction of Bill C-64, An Act respecting pharmacare (Pharmacare Act).Read More -
PMPRB releases 2022 Annual Report and March 2024 NEWSletter
On February 16, 2024, the Minister of Health tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB).Read More